Evotec SE (EVT) - Total Assets
Based on the latest financial reports, Evotec SE (EVT) holds total assets worth €1.64 Billion EUR (≈ $1.92 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore EVT cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Evotec SE - Total Assets Trend (2001–2025)
This chart illustrates how Evotec SE's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Evotec SE for net asset value and shareholders' equity analysis.
Evotec SE - Asset Composition Analysis
Current Asset Composition (December 2025)
Evotec SE's total assets of €1.64 Billion consist of 42.9% current assets and 57.1% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €418.52 Million | 23.5% |
| Accounts Receivable | €213.51 Million | 12.0% |
| Inventory | €29.32 Million | 1.7% |
| Property, Plant & Equipment | €554.63 Million | 31.2% |
| Intangible Assets | €31.57 Million | 1.8% |
| Goodwill | €272.37 Million | 15.3% |
Asset Composition Trend (2001–2025)
This chart illustrates how Evotec SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EVT market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Evotec SE's current assets represent 42.9% of total assets in 2025, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 23.5% of total assets in 2025, up from 0.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 16.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is property, plant & equipment at 31.2% of total assets.
Evotec SE Competitors by Total Assets
Key competitors of Evotec SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Evotec SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.68 | 2.03 | 2.84 |
| Quick Ratio | 1.60 | 1.93 | 2.78 |
| Cash Ratio | 0.00 | 0.80 | 0.00 |
| Working Capital | €287.90 Million | €366.96 Million | €440.80 Million |
Evotec SE - Advanced Valuation Insights
This section examines the relationship between Evotec SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.24 |
| Latest Market Cap to Assets Ratio | 0.41 |
| Asset Growth Rate (YoY) | -7.0% |
| Total Assets | €1.78 Billion |
| Market Capitalization | $724.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values Evotec SE's assets below their book value (0.41x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Evotec SE's assets decreased by 7.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Evotec SE (2001–2025)
The table below shows the annual total assets of Evotec SE from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €1.78 Billion ≈ $2.08 Billion |
-6.99% |
| 2024-12-31 | €1.91 Billion ≈ $2.24 Billion |
-15.09% |
| 2023-12-31 | €2.25 Billion ≈ $2.63 Billion |
-0.21% |
| 2022-12-31 | €2.26 Billion ≈ $2.64 Billion |
+0.99% |
| 2021-12-31 | €2.24 Billion ≈ $2.61 Billion |
+52.79% |
| 2020-12-31 | €1.46 Billion ≈ $1.71 Billion |
+23.88% |
| 2019-12-31 | €1.18 Billion ≈ $1.38 Billion |
+52.99% |
| 2018-12-31 | €771.88 Million ≈ $902.41 Million |
+15.68% |
| 2017-12-31 | €667.27 Million ≈ $780.11 Million |
+89.91% |
| 2016-12-31 | €351.37 Million ≈ $410.78 Million |
+21.77% |
| 2015-12-31 | €288.54 Million ≈ $337.33 Million |
+28.47% |
| 2014-12-31 | €224.60 Million ≈ $262.58 Million |
-1.22% |
| 2013-12-31 | €227.38 Million ≈ $265.83 Million |
+0.87% |
| 2012-12-31 | €225.43 Million ≈ $263.55 Million |
+3.31% |
| 2011-12-31 | €218.21 Million ≈ $255.11 Million |
+13.74% |
| 2010-12-31 | €191.86 Million ≈ $224.30 Million |
+30.87% |
| 2009-12-31 | €146.60 Million ≈ $171.39 Million |
-19.85% |
| 2008-12-31 | €182.90 Million ≈ $213.83 Million |
-12.02% |
| 2007-12-31 | €207.88 Million ≈ $243.03 Million |
+1.14% |
| 2006-12-31 | €205.53 Million ≈ $240.28 Million |
+10.43% |
| 2005-12-31 | €186.11 Million ≈ $217.58 Million |
+162.46% |
| 2004-12-31 | €70.91 Million ≈ $82.90 Million |
+69.94% |
| 2003-12-31 | €41.73 Million ≈ $48.78 Million |
+123.10% |
| 2002-12-31 | €18.70 Million ≈ $21.87 Million |
-48.34% |
| 2001-12-31 | €36.20 Million ≈ $42.33 Million |
-- |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more